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T he nonapeptide bradykinin and related kinins
are intimately involved in a wide number of pathophysiological states. Although bradykinin causes hypotension due to arteriolar dilation, kinins may contract isolated blood vessels such as the rabbit aorta and jugular vein (for review see References 1 and 2). Studies on the structure-activity relations of several bradykinin analogues 1 have led to the characterization of two classes of bradykinin receptors, named B 1 and B 2 . Thus, the B 1 bradykinin receptors are more restricted to some vascular beds and exhibit higher affinity for kinin metabolites such as des-Arg'-bradykinin and des-Arg 9 -kallidin and are selectively antagonized by the B! receptor antagonists des-Arg'.tLeu^-bradykinin and des-Arg'^Leu^-kallidin. In contrast, the B 2 receptors present high affinities for bradykinin and kallidin, are usually widely distributed throughout mammalian tissues, and mediate a great number of kinin responses either in physiological or pathological states. There is now substantial evidence suggesting the heterogeneity of B 2 receptors 3 (for review see References 4 and 5). Furthermore, bradykinin responses mediated by B, but not by B 2 receptors have been associated with certain pathological conditions, and these responses are enhanced as a function of the incubation period when analyzed in vitro, possibly by de novo synthesis of B, receptors. 5 " 8 It has been proposed that bradykinin signal transduction and second-messenger mechanisms in many cell types involve the breakdown of phosphatidylinositol through the activation of phosphatidylinositolspecific phospholipase C. This leads to an increase in inositol trisphosphate, which releases intracellular Ca 2+ and diacylglycerol, which activates protein kinase C. In other tissues, bradykinin responses involve Supplement II Hypertension Vol 19, No 2 February 1992 the stimulation of phospholipase A 2 , which in turn determines the release of arachidonic acid and prostaglandin synthesis (for review see References 4 and 9). However, the role of these mechanisms in bradykinin-mediated responses of vascular muscles is not completely understood. In this study, we examined the influence of Ca 2+ mobilization and protein kinase C inhibitors on bradykinin-induced contractions via stimulation of B, and Bj receptors in rabbit aorta (RA) and jugular vein (JV).
Methods
White rabbits of both sexes (1.5-2.5 kg) were killed by a blow on the head and exsanguinated. The thoracic RA and JV were carefully excised and cleaned of connective tissues. Rings (6-8 mm wide) were set up in a 5-ml organ bath chamber containing Krebs-Henseleit solution at 37°C, pH 7.2, and were gassed with 95% 0^5 % CO 2 . The Krebs' solution had the following composition (mM): N a d 113, KC1 4.7, CaCl 2 2.5, MgSO 4 1.1, KH 2 PO 4 1.1, and glucose 11. Isometric tension changes were recorded by means of an F-60 force transducer (Narco Biosystem) under a 0.5-g and 1-g resting load for JV and RA, respectively. Preparations were equilibrated for 1 hour (JV) and 3 hours (RA), then captopril (3 /xM) was added to the bath solution and the experiments were started. Bath solution was renewed every 20 minutes during the experiments. Usually, four preparations were obtained from the tissues of each animal, and these were used in parallel but in different experiments.
In some experiments, the vascular endothelium was removed intentionally by gentle rubbing of the internal vessel surface with a cotton tip. Endothelium integrity was assessed by the ability of acetylcholine (1 fiM) to produce relaxation of preparations precontracted with norepinephrine (10-100 nM). After the equilibration period, complete cumulative contractile concentration-response curves were obtained for bradykinin (0.001 nM to 10 fiM) at 60-minute intervals. To examine the influence of endothelium on bradykinin-induced contraction after obtaining the contractile response to KC1 (80 mM, prepared by equimolar substitution of NaCl by KG), we obtained dose-response curves for bradykinin in RA and JV rings with and without endothelium. To assess the influence of extracellular Ca 2+ on bradykinininduced contractions after obtaining a control curve for bradykinin in normal Krebs' solution, we placed the preparations for 30 minutes in Krebs' solution free of Ca 2+ or in Ca
2+
-free solution plus EGTA (1 mM) and then obtained other curves for bradykinin.
In separate experiments, after a control response to bradykinin was obtained, the preparations were preincubated with nicardipine (1 /AM) or NiG 2 (0.1-0.3 mM) for 20 minutes, and new responses to bradykinin were obtained in their presence. In some tissues, after a simple response to bradykinin (100 nM or 3 /AM) or to norepinephrine (1 fjM) was obtained, the preparations were transferred to Ca 2+ -free solution containing EGTA (1 mM), and several responses to bradykinin were obtained after Ca 2+ withdrawal at 30-minute intervals.
The contribution of Ca 2+ from intracellular sources to bradykinin-mediated responses in both tissues was also analyzed. After a control response to bradykinin in normal medium was obtained, the preparations were preincubated for 20 minutes with ryanodine (30 uM), either in normal medium or in Ca
-free solution, and new curves were constructed for bradykinin in its presence. Finally, to examine the possible participation of protein kinase C on bradykinin-induced contractions, after obtaining a control contractile response to bradykinin, we exposed tissues to staurosporine (1-100 nM) or l-(5-isoquinoUnesulfonyl)-2-methylpiperizine (H-7) (3 and 10 /u.M) for 30 minutes or to phorbol ester (1 fiM for 30 and 60 minutes) and obtained new responses to bradykinin in their presence. In all experimental groups, parallel time-matched control experiments were performed for bradykinin alone in strips obtained from the same animal. Usually, contractile responses to bradykinin remained constant over the time course of the experiments.
Drugs
Drugs used were bradykinin, H-7, nicardipine, phorbol 12-myristate 13-acetate, captopril (all from Sigma Chemical Co., St. Louis, Mo.), ryanodine (Research Biochemicals Inc., Natick, Mass.), staurosporine (Boehringer, Mannheim, FRG), and NiCl 2 (Riedel-de Haen, Seelze, FRG). Bradykinin, NiCl 2 , H-7, and captopril were prepared in phosphate buffered saline; staurosporine in dimethyl sulfoxide; and all other drugs in absolute ethanol. The final ethanol and dimethyl sulfoxide bath concentrations were less than 0.2%. Appropriate parallel control experiments were carried out with only the vehicles used to dilute these drugs.
Statistical Analysis
Data are expressed as mean±SEM, except ECjo values, which are reported as the geometric means and their respective 95% confidence limits. The EQo values were calculated from linear regression analysis from the complete concentration-response curves by means of a computer program. Data were analyzed by Student's t test for unpaired samples or by analysis of variance followed by Dunnett's multiple comparison test, when appropriate. A value of p<0.05 was considered significant.
Results

Influence of Endothelium
In intact RA rings, bradykinin (0.1-22 /iM) elicited a slow tonic concentration-dependent contractile response and a complete curve demanded approximately 40 minutes. Mean EQo (and 95% confidence limits) was 1.6 (1.2-2.2) fiM, and the maximal response was 2.1±0.2 g (n=26), being approximately 66% relative to that elicited by KC1 (80 mM) ( Figure 1A ). However, approximately 10% of the preparations failed to respond to bradykinin. Removal of the endothelium did not significantly affect either the sensitivity or the maximal tension elicited by bradykinin ( Figure 1A ). In contrast, in JV rings, bradykinin (0.1-1,000 nM) caused a more rapid tonic contraction, being about three orders of magnitude more potent than in RA, an EQo of 2.2 (1.3-3.7) nM (n=24), and maximal tension of 2.4±0.2 g, corresponding to 457% of the contraction elicited by KC1 (80 mM) ( Figure IB) . In JV preparations without endothelium, the curve for bradykinin was markedly shifted to the left (approximately 1,000-fold) with an EQo of 2.8 (1.1-7.6) pM, allied with a significant depression of the maximal response (1.6±0.3 g) ( Figure IB) .
Influence of Calcium
Results in Figure 2A show that incubation of RA with Ca 2+ -free solution for 30 minutes caused a marked rightward shift of the bradykinin dose-response curve, with no change in the maximal response. In addition, in the presence of Ca 2+ -free solution plus EGTA (1 mM), the response to bradykinin was further inhibited. However, because of a limited supply of bradykinin, a complete concentration-response curve for this peptide could not be obtained under these conditions. Similar experiments carried out in JV rings revealed that omission of Ca 2+ from the Krebs' solution caused a rightward shift of the bradykinin dose-response curves, allied with a marked depression of maximal tension ( Figure 2B ).
However, when JV rings were exposed to Ca 2+ -free solution containing EGTA (1 mM) for 30 minutes, no additional inhibition was observed. Preincubation of both preparations with nicardipine (1 JAM), a blocker of L-type voltage-sensitive Ca 2+ channels, for 20 minutes did not significantly change bradykinin-induced responses in either preparation ( Figures 3A and 3B) . Interestingly, when RA was preincubated with NiQ 2 (0.1-0.3 mM), a T-type Ca 2+ channel blocker, for 20 minutes, a dose-dependent and parallel rightward displacement of the bradykinin dose-response curve was observed (dose ratio, 2 to 8), with no significant change in the maximal contraction ( Figure 3A ). Responses to bradykinin in JV were also dosedependently shifted to the right in the presence of NiCl 2 , allied with a marked depression of maximal response ( Figure 3B) .
The typical records shown in Figures 4A duced a very modest contraction that was more sensitive to external Ca 2+ removal ( Figure 4B ). The effect of ryanodine (30 ^.M) either in normal medium or in Ca 2+ -free Krebs' solution against bradykinin-induced contractions in both preparations is depicted in Figure 5 . Ryanodine added to normal Krebs' solution 30 minutes beforehand did not significantly interfere with bradykinin-induced contractions in either tissue. However, when this alkaloid was preincubated in Ca 2+ -free Krebs' solution, it markedly antagonized bradykinin-induced contractions in JV but caused no additional inhibition in RA compared with experiments performed in Ca 2+ -free solution ( Figure 5 ).
Influence of Protein Kinase C
Staurosporine (1-100 nM), a reported putative protein kinase C inhibitor, preincubated in the bath for 30 minutes, caused a dose-dependent rightward displacement of the dose-response curve for bradykinin in JV, allied with a marked depression of maximal response with an IQo value of approximately 10 nM ( Figure 6B ). In RA, staurosporine (10-100 nM) also promoted a dose-dependent rightward shift of the bradykinin dose-response curve but caused less inhibition in the maximal response (Figure 6A ). H-7 (3 and 10 iiM), another reported protein kinase C inhibitor, caused a dose-dependent inhibition of bradykinin-induced contractile response in JV, associated with a slight rightward shift of the bradykinin dose-response curve (control maximal response of 2.2±0.2 versus 1.7±0.1 and 1.2±0.1 g in the presence of 3 and 10 nM of H-7, respectively; n=5). In the same concentration range, H-7 failed to affect bradykinin-induced contractions in RA (n=3) (results not shown). The activator of protein kinase C phorbol 12-myristate 13-acetate (1 jiM) added to the preparations either 30 or 60 minutes before did not significantly interfere with bradykinin-induced contraction in RA but caused a slight inhibition of bradykinin-induced contraction in JV ( Figures 6A  and 6B ). In addition, phorbol ester (1 fiM) caused a slow contractile response in JV but did not cause any effect in RA (results not shown).
Discussion
The results of the present study demonstrate that bradykinin causes a graded concentration-dependent contractile response in RA and JV rings and indicate that there are substantial differences in the mechanisms that underlie the contractile responses for this peptide in the two preparations. Although responses to bradykinin in RA are not influenced by vascular Regarding the sources of Ca 2+ used for bradykinininduced muscular contractions in these preparations, our data indicate that responses induced by this peptide in RA and JV are dependent on both extracellular Ca 2+ influx and Ca 2+ release from intracellular sources. This view is supported by the fact that immersion of both tissues in Ca 2+ -free solution for 30 minutes markedly attenuated bradykinin-induced contraction in both tissues. Addition of EGTA (1 mM) to the Ca 2+ -free solution caused a further inhibition of bradykinin-mediated contraction in RA but not in JV. This implies that bradykinin-induced contractions in RA appear to be exclusively or nearly exclusively mediated by extracellular superficial membrane-bound Ca 2+ , which is very sensitive to EGTA, whereas the contractile responses caused by this peptide in JV may depend on both extracellular and intracellular Ca 2+ release. However, the possibility that prolonged exposure of RA to EGTA may attenuate bradykinin-induced contraction by direct action in intracellular Ca 2+ stores rather than by removal of the extracellular superficially bound Ca 2+ cannot be fully discarded.
1011 Furthermore, the timecourse experiments carried out for bradykinin in Ca 2+ -free solution plus EGTA provide further evidence indicating that both extracellular and intracellular mobilization of Ca 2+ sources appear to be involved in bradykinin-mediated contractile response in RA and JV. Interestingly, the contractile responses elicited by bradykinin in both preparations are resistant to the action of nicardipine. However, nicardipine (1-1,000 nM) caused a dose-dependent inhibition of KCl-induced contraction in both RA and JV rings (results not shown). This suggests that L-type Ca 2+ channels are functionally present in these preparations. Thus, the stimulation of extracellular Ca 2+ influx by bradykinin presumably involves mechanisms other than the activation of voltagesensitive L-type Ca 2+ channels. Alternatively, bradykinin-induced contractions in both RA and JV may involve extracellular Ca 2+ influx via receptor-operated Ca 2+ channels. Moreover, bradykinin-evoked contractions in RA and to a lesser extent in JV were markedly inhibited in the presence of nickel, indicating that T-type Ca 2+ channels 12 may contribute to some extent to Ca 2+ influx in response to bradykinin. However, the relative contribution of this mechanism to bradykinin-induced contractions in both tissues requires additional investigation.
It has been extensively demonstrated that ryanodine, a neutral alkaloid, affects muscle contraction by either opening or closing the sarcoplasmic reticulum Ca 2+ channels. 1314 The proposed intracellular ryanodine receptor has been isolated and purified. More recently, Takeshima et al 15 described the primary structure of the ryanodine receptor responsible for Ca 2+ release from sarcoplasmic reticulum of skeletal muscle during excitation-contraction coupling. This receptor seems to be a tetramer of four transmembrane segments very similar to the putative receptor for inositol 1,4,5-trisphosphate. 16 - 17 The inhibition observed for ryanodine against bradykinin-induced contractions in JV but not in RA furnishes additional evidence indicating that bradykinin-mediated contraction in the former tissue may involve release of intracellular Ca 2+ rather than Ca 2+ influx from extracellular sources. Similar ryanodine inhibition has The dose-dependent inhibition of bradykinin-induced contractions in JV rings that was obtained in the presence of low concentrations of staurosporine (1-100 nM) or H-7 (3 and 10 fiM), two reported putative protein kinase C inhibitors, 21 -22 strongly suggests that the bradykinin-mediated contractile effect in this preparation may be intimately related to the activation of protein kinase C, possibly through stimulation of phosphatidylinositol turnover and formation of diacylglycerol, as already reported for this peptide in other tissues. 4 - 5 The greater potencies of both drugs in inhibiting contraction caused by bradykinin in rabbit JV argue in favor of their actions being mediated by protein kinase C inhibition rather than by inhibition of other enzymes, because these substances present some nonspecific actions. 23 - 24 The results indicating that phorbol 12-myristate 13-acetate (1 ^M), a specific activator of protein kinase C, 25 caused a slow tonic contraction in JV but was virtually without effect in RA furnish additional support in favor of the involvement of protein kinase C in the bradykinin-mediated contractile response in the former preparation. In addition, preincubation of the preparations with phorbol ester for 30 or 60 minutes significantly depressed maximal response to bradykinin in JV but did not cause any significant effect on bradykinin-induced contraction in RA. This suggests that B] and B2 bradykinin receptors present in RA and JV, respectively, may be coupled to different second-messenger mechanisms. Besides stimulating protein kinase C in smooth muscles, phorbol esters can also inhibit the hydrolysis of phosphoinositides and the contraction mediated by release of inositol phosphate in response to several agonists. 26 - 27 Additionally, phorbol esters have been reported to stimulate the influx of Ca 2+ in vascular smooth muscle, including rat and rabbit aorta. 28 - 29 This last mechanism may help to explain the strong tonic contractile response elicited by this diterpene in JV.
In summary, the results of the present study provide evidence indicating that the mechanisms underlying the contractile responses to bradykinin in rings of RA and JV differ greatly. In RA, contractions elicited by bradykinin through stimulation of B, receptors involve essentially, if not exclusively, the utilization of superficial Ca 2+ sources that are very sensitive to EGTA. In contrast, the contractile responses to bradykinin in JV through activation of B2 receptors are dependent on both extracellular Ca 2+ influx and intracellular Ca 2+ release that is greatly inhibited by ryanodine. However, the influx of Ca 2+ in response to bradykinin in both tissues does not appear to be related to the activation of dihydropyridine voltage-sensitive L-type Ca 2+ channels, but responses to bradykinin in both tissues were inhibited by nickel, a T-type antagonist of Ca 2+ channels. Furthermore, responses to bradykinin in JV but not in RA appear to be coupled to activation of protein kinase C. Thus, the differences in the bradykinin mechanism of action between the two preparations are most certainly related to the presence of different subtypes of bradykinin receptors, which may be coupled to distinct second-messenger mechanisms.
